Chinese genome sequencing company BGI-Shenzhen is working with Brunswick Group in the U.S. and China as it moves to acquire Silicon Valley-based Complete Genomics in a cash tender worth $117.6M.
Waggener Edstrom works with CG, which said the deal came after reviewing “alternatives” with its outside advisors.
The $3.15-per-share deal will make CG a subsidiary of Shenzen-based BGI, which has also engaged proxy firm Innisfree M&A.
Brunswick’s San Francisco and Hong Kong offices are supporting media relations and PR counsel for BGI.
The combination of the companies' resources provides an opportunity to accelerate our vision of providing researchers and physicians with the genomic information needed to prevent, diagnose, and treat cancers and other genetic diseases,” Dr. Clifford Reid, chairman and CEO of Complete, said in a statement.
The cost of genetic sequencing has fallen in recent years as technology improves, increasing its potential for medical research and the development of treatments.